| Revised upper limb module for spinal muscular atrophy: development of a new module ES Mazzone, A Mayhew, J Montes, D Ramsey, L Fanelli, SD Young, ... Muscle & nerve 55 (6), 869-874, 2017 | 235 | 2017 |
| Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial E Mercuri, F Muntoni, G Baranello, R Masson, O Boespflug-Tanguy, ... The Lancet Neurology 20 (10), 832-841, 2021 | 151 | 2021 |
| Developmental milestones in type I spinal muscular atrophy R De Sanctis, G Coratti, A Pasternak, J Montes, M Pane, ES Mazzone, ... Neuromuscular Disorders 26 (11), 754-759, 2016 | 146 | 2016 |
| Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled … E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, ... The Lancet Neurology 21 (1), 42-52, 2022 | 139 | 2022 |
| Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy MC Pera, G Coratti, N Forcina, ES Mazzone, M Scoto, J Montes, ... BMC neurology 17, 1-10, 2017 | 132 | 2017 |
| Nusinersen in type 1 spinal muscular atrophy: twelve‐month real‐world data M Pane, G Coratti, VA Sansone, S Messina, C Bruno, M Catteruccia, ... Annals of neurology 86 (3), 443-451, 2019 | 108 | 2019 |
| Ambulatory function in spinal muscular atrophy: age-related patterns of progression J Montes, MP McDermott, E Mirek, ES Mazzone, M Main, AM Glanzman, ... PLoS One 13 (6), e0199657, 2018 | 83 | 2018 |
| Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function M Pane, C Palermo, S Messina, VA Sansone, C Bruno, M Catteruccia, ... Neuromuscular Disorders 28 (7), 582-585, 2018 | 79 | 2018 |
| Revised upper limb module for spinal muscular atrophy: 12 month changes MC Pera, G Coratti, ES Mazzone, J Montes, M Scoto, R De Sanctis, ... Muscle & nerve 59 (4), 426-430, 2019 | 74 | 2019 |
| Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis G Coratti, C Cutrona, MC Pera, F Bovis, M Ponzano, F Chieppa, ... Orphanet Journal of Rare Diseases 16, 1-12, 2021 | 73 | 2021 |
| Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen VA Sansone, A Pirola, E Albamonte, M Pane, A Lizio, A D'Amico, ... The Journal of pediatrics 219, 223-228. e4, 2020 | 69 | 2020 |
| Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? MC Pera, G Coratti, B Berti, A D’Amico, M Sframeli, E Albamonte, ... PLoS One 15 (3), e0230677, 2020 | 64 | 2020 |
| Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 C Brogna, G Coratti, M Pane, V Ricotti, S Messina, A D’Amico, C Bruno, ... PLoS One 14 (6), e0218683, 2019 | 62 | 2019 |
| Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy R De Sanctis, M Pane, G Coratti, C Palermo, D Leone, MC Pera, E Abiusi, ... Neuromuscular Disorders 28 (1), 24-28, 2018 | 62 | 2018 |
| Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy E Mercuri, G Coratti, S Messina, V Ricotti, G Baranello, A D’Amico, ... PLoS One 11 (8), e0160195, 2016 | 62 | 2016 |
| Longitudinal natural history of type I spinal muscular atrophy: a critical review E Mercuri, S Lucibello, M Perulli, G Coratti, R De Sanctis, MC Pera, ... Orphanet Journal of Rare Diseases 15, 1-7, 2020 | 57 | 2020 |
| Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data M Pane, G Coratti, C Brogna, ES Mazzone, A Mayhew, L Fanelli, ... PLoS One 13 (6), e0199223, 2018 | 54 | 2018 |
| Performance of Upper Limb module for Duchenne muscular dystrophy AG Mayhew, G Coratti, ES Mazzone, K Klingels, M James, M Pane, ... Developmental medicine & child neurology 62 (5), 633-639, 2020 | 47 | 2020 |
| Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial R Masson, M Mazurkiewicz-Bełdzińska, K Rose, L Servais, H Xiong, ... The Lancet Neurology 21 (12), 1110-1119, 2022 | 44 | 2022 |
| Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients M Pane, G Coratti, VA Sansone, S Messina, M Catteruccia, C Bruno, ... Annals of Clinical and Translational Neurology 8 (3), 548-557, 2021 | 44 | 2021 |
